Literature DB >> 1551417

Substrate and inhibitor studies on proteinase 3.

C M Kam1, J E Kerrigan, K M Dolman, R Goldschmeding, A E Von dem Borne, J C Powers.   

Abstract

Various amino acid and peptide thioesters were tested as substrates for human proteinase 3 and the best substrate is Boc-Ala-Ala-Nva-SBzl with a kcat/Km value of 1.0 x 10(6) M-1.s-1. Boc-Ala-Ala-AA-SBzl (AA = Val, Ala, or Met) are also good substrates with kcat/Km values of (1-4) x 10(5) M-1.s-1. Substituted isocoumarins are potent inhibitors of proteinase 3 and the best inhibitors are 7-amino-4-chloro-3-(2-bromoethoxy)isocoumarin and 3,4-dichloroisocoumarin (DCI) with kobs/[I] values of 4700 and 2600 M-1.s-1, respectively. Substituted isocoumarins, peptide phosphonates and chloromethyl ketones inhibited proteinase 3 less potently than human neutrophil elastase (HNE) by 1-2 orders of magnitude.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551417     DOI: 10.1016/0014-5793(92)80340-m

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  14 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Iterative Optimization of the Cyclic Peptide SFTI-1 Yields Potent Inhibitors of Neutrophil Proteinase 3.

Authors:  Sixin Tian; Joakim E Swedberg; Choi Yi Li; David J Craik; Simon J de Veer
Journal:  ACS Med Chem Lett       Date:  2019-07-19       Impact factor: 4.345

3.  Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3.

Authors:  C Coeshott; C Ohnemus; A Pilyavskaya; S Ross; M Wieczorek; H Kroona; A H Leimer; J Cheronis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

4.  Role of polymorphonuclear leukocyte-derived serine proteinases in defense against Actinobacillus actinomycetemcomitans.

Authors:  Susanne F de Haar; Pieter S Hiemstra; Martijn T J M van Steenbergen; Vincent Everts; Wouter Beertsen
Journal:  Infect Immun       Date:  2006-09       Impact factor: 3.441

5.  Inhibition of serine proteases by a new class of cyclosulfamide-based carbamylating agents.

Authors:  Qingliang Yang; Yi Li; Dengfeng Dou; Xiangdong Gan; Swathi Mohan; Christopher S Groutas; Laura E Stevenson; Zhong Lai; Kevin R Alliston; Jiaying Zhong; Todd D Williams; William C Groutas
Journal:  Arch Biochem Biophys       Date:  2008-04-22       Impact factor: 4.013

6.  Mechanism-based inhibitors of serine proteases with high selectivity through optimization of S' subsite binding.

Authors:  Yi Li; Dengfeng Dou; Guijia He; Gerald H Lushington; William C Groutas
Journal:  Bioorg Med Chem       Date:  2009-04-12       Impact factor: 3.641

7.  Interference of Wegener's granulomatosis autoantibodies with neutrophil Proteinase 3 activity.

Authors:  B A van de Wiel; K M Dolman; C H van der Meer-Gerritsen; C E Hack; A E von dem Borne; R Goldschmeding
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

8.  Utilization of the 1,2,3,5-thiatriazolidin-3-one 1,1-dioxide scaffold in the design of potential inhibitors of human neutrophil proteinase 3.

Authors:  Dengfeng Dou; Guijia He; Yi Li; Zhong Lai; Liuqing Wei; Kevin R Alliston; Gerald H Lushington; David M Eichhorn; William C Groutas
Journal:  Bioorg Med Chem       Date:  2009-12-29       Impact factor: 3.641

9.  X-ray snapshot of the mechanism of inactivation of human neutrophil elastase by 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives.

Authors:  Weijun Huang; Yasufumi Yamamoto; Yi Li; Dengfeng Dou; Kevin R Alliston; Robert P Hanzlik; Todd D Williams; William C Groutas
Journal:  J Med Chem       Date:  2008-03-05       Impact factor: 7.446

10.  Structural and functional characterization of elastases from horse neutrophils.

Authors:  A Dubin; J Potempa; J Travis
Journal:  Biochem J       Date:  1994-06-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.